BillionToOne Sets Third-Quarter 2026 Results Release for November 4
BillionToOne, Inc. said on October 14, 2026 that it plans to release its financial results for the third quarter ended September 30, 2026 after the market close on Wednesday, November 4, 2026. The molecular diagnostics company will host a conference…
Boston Robotic Lab Slated for NSF X-Labs Under Ginkgo Pledge
Ginkgo Bioworks announced on Thursday, October 8, 2026, that it will provide in-kind access to its autonomous laboratory in Boston to research teams participating in the National Science Foundation’s X-Labs program, contributing cloud lab time and protein testing services to…
Caribou Biosciences to Discontinue CAR-T Programs, Opens Strategic Review
Caribou Biosciences announced on October 6, 2026 that it is exploring strategic alternatives to maximize stockholder value and plans to discontinue further development of its two allogeneic CAR-T cell therapy programs, vispa-cel for relapsed or refractory B cell non-Hodgkin lymphoma…
Twist Bioscience to Provide Antibody Data Services for Lilly TuneLab
Twist Bioscience Corporation announced on September 16, 2026 an agreement with Lilly TuneLab, a collaborative artificial intelligence and machine learning drug discovery platform created by Eli Lilly and Company . Under the agreement, the South San Francisco-based company is a…
Novo Nordisk Buys Ginkgo Autonomous Lab for New Waltham R&D Site
Ginkgo Bioworks announced on September 15, 2026 that it has been selected to build an autonomous lab powered by its Reconfigurable Automation Cart (RAC) architecture at Novo Nordisk’s new U.S. research and development site in Waltham, Massachusetts. Novo Nordisk purchased…
FDA Grants Priority Review to Intellia BLA for CRISPR Therapy Lonvo-Z
Intellia Therapeutics announced on September 8, 2026, that the U.S. Food and Drug Administration has accepted its Biologics License Application for lonvoguran ziclumeran (lonvo-z) in hereditary angioedema and granted the filing Priority Review, setting a Prescription Drug User Fee Act…
Intellia Therapeutics Lands Up to $400 Million in Non-Dilutive OrbiMed Term Loan
Intellia Therapeutics entered into a non-dilutive senior secured term loan facility with healthcare investment firm OrbiMed on September 4, 2026, the gene editing company announced. The facility provides for up to $400 million, with $75 million funded upfront and an…
